Arch Bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Pretzel Gets $72.5M for Gene Editing & Small Molecules Against Mitochondrial Targets
Neumora Secures $500M, Amgen Deal, in Quest for Precision Neuroscience R&D
Investing in Manufacturing, Mental Health & More: Bob Nelsen on The Long Run
Overcoming a Bad Job Market, Finding a Path in Biotech: Sabah Oney on The Long Run